MedDataX Logo

Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer Patients

NCT ID: NCT00213798

Last Updated: 2025-12-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-12-31

Study Completion Date

2011-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The majority of lung cancer patients have a tumor-derived genetic alteration in circulating plasma DNA that could be exploited as a diagnostic tool. The aim of this study is to evaluate if plasma DNA can be used as a valuable non invasive test to monitor disease progression without assessing the tumor.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Small Cell Lung Carcinoma Small Cell Lung Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Lung cancer plasma DNA allelotyping follow-up Prospective Study Non-Small Cell Lung Cancer Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biopsy samples

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Presence of lung tumor to use fiberoscopy or surgical intervention for diagnosis.
* No lung instability.
* Individuals give all informed consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Strasbourg, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michèle BEAU-FALLER, MD

Role: PRINCIPAL_INVESTIGATOR

Service de Pneumologie, Hôpital de Hautepierre

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Service de Pneumologie, Hôpital Lyautey

Strasbourg, , France

Site Status

Service de Chirurgie Thoracique, Hôpital Civil

Strasbourg, , France

Site Status

Service de Pneumologie, Hôpital Civil

Strasbourg, , France

Site Status

Service de Pneumologie, Hôpital de Hautepierre

Strasbourg, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Beau-Faller M, Gaub MP, Schneider A, Ducrocq X, Massard G, Gasser B, Chenard MP, Kessler R, Anker P, Stroun M, Weitzenblum E, Pauli G, Wihlm JM, Quoix E, Oudet P. Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients. Int J Cancer. 2003 Jun 20;105(3):361-70. doi: 10.1002/ijc.11079.

Reference Type RESULT
PMID: 12704670 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2731

Identifier Type: -

Identifier Source: org_study_id